According to researchers at GlaxoSmithKline, a new shingles vaccine called Shingrix is far more effective to prevent the extremely painful skin rash than the vaccine that is currently on the market. It reportedly reduces the risk to adults aged 50 and older by 97.2 percent. The current vaccine Zostavax is only about 70 percent effective and its efficacy drops to below 40 percent in people 70 and older.
Shingrix isn’t on the market yet, but The Advisory Committee on Immunization Practices (ACIP) voted recently to recommend the vaccine to anyone over 50, over the existing vaccine. The ACIP will make their recommendations to the Centers for Disease Control and Prevention and if the CDC follows the Committee’s recent vote, it will update its advice by recommending Shingrix. The Food and Drug Administration approved the new vaccine in late October.